GlassScriptPhysician profile
Sindhu Gupta
NPI 1548256183
$3,182.72
in general payments reported to CMS, 2019-2025
25 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $267 · 2021: $452 · 2022: $658 · 2023: $482 · 2024: $366 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.16 |
| Education | $211.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,105.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $312.07 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Sanofi-Aventis U.S. LLC | $236.36 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $219.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $194.28 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $128.65 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Genzyme Corporation | $115.90 | 2023-2025 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Lilly USA, LLC | $98.30 | 2020-2024 | Zepbound, Mounjaro, Jardiance |
| Actelion Pharmaceuticals US, INC. | $89.00 | 2022 | |
| Abbott Laboratories | $85.71 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $62.55 | 2019-2021 | |
| Exact Sciences Corporation | $52.67 | 2024-2025 | Cologuard Collection Kit |
| Csl Behring | $42.45 | 2025 | Andembry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $31.01 | 2025 | Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $30.46 | 2021 | |
| Biocryst US Sales Co., LLC | $28.90 | 2025 | |
| Horizon Therapeutics Plc | $27.19 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $18.96 | 2025 | Recorlev |
| Kowa Pharmaceuticals America, INC. | $18.28 | 2023 | Livalo |
| Amgen INC. | $18.05 | 2025 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $15.90 | 2022 | |
| Pfizer INC. | $15.47 | 2024 | |
| Esperion Therapeutics, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.